Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis
Shots:
- The P-III DISCOVER-2a study involves assessing Tremfya (q4w/ q8w- SC) in bio-naïve patients with active PsA
- Results: @100wks. complete skin clearance (PASI 100) (59 %/53%); improvement in joint symptoms (ACR 20) (76%/74%). The findings confirmed that the robust efficacy of Tremfya demonstrated in patients @24wks. on physical function- physical aspects of health-related QoL- and resolution of enthesitisb and dactylitisc was also seen through 100wks.
- Additionally- the extent of radiographic progression was studied through 2yrs. Tremfya is the first and only IL-23 inhibitor therapy approved in the US to treat with active PsA and PsO
Ref: J&J | Image: Euro Finance
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com